文献速递神经肿瘤功能神经外科

肢端肥大症重复放射外科治疗的安全性与疗效:国际多中心研究

Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study.
PubMed 文献 · J Neurooncol · 2019-09-20

重复治疗后中位影像随访3.4年、内分泌随访3.8年,18例可评估影像者中15例(83.3%)肿瘤控制,21例可评估内分泌者中9例(42.9%)内分泌缓解,4例(19.0%)出现新发缺陷。

要点

  • 重复SRS后肿瘤控制率83.3%(15/18),内分泌缓解率42.9%(9/21)。
  • 重复SRS后新发缺陷发生率为19.0%(4/21)。
  • 初次至重复SRS中位间隔5.0年,重复中位边缘剂量23 Gy。

核心结论

  • 对于持续性肢端肥大症患者,重复放射外科治疗提供了合理的获益-风险比。
  • 仍需进一步研究以确定最适合该治疗方法的患者。

研究设计与样本

  • 回顾性多中心队列研究,数据来源于国际伽玛刀研究基金会数据库。

主要发现

  • 重复SRS后中位影像随访3.4年,18例中15例(83.3%)达到肿瘤控制。
  • 重复SRS后中位内分泌随访3.8年,21例中9例(42.9%)达到内分泌缓解。
  • 4例(19.0%)在重复放射外科治疗后出现新发缺陷,其中3例为神经功能缺陷、1例为内分泌缺陷。
  • 初次SRS至重复SRS的中位时间为5.0年。
  • 初次SRS中位边缘剂量为17 Gy,重复SRS中位边缘剂量为23 Gy。

关键数值与推荐

  • 肿瘤控制定义为影像学上无腺瘤进展。
  • 内分泌缓解定义为停用药物治疗时IGF-1浓度正常。

临床怎么用

  • 对于初次SRS后未达到内分泌缓解的肢端肥大症患者,重复SRS可作为考虑选项。
  • 重复SRS前应评估获益与新发缺陷风险,并向患者说明约19.0%的新发缺陷发生率。

局限性

  • 样本量小(21例内分泌随访、18例影像随访)。
  • 为回顾性研究,来自数据库登记资料。
  • 随访时间有限(中位影像3.4年、内分泌3.8年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Surgical resection is the first line treatment for growth hormone (GH) secreting tumors. Stereotactic radiosurgery (SRS) is recommended for patients who do not achieve endocrine remission after resection. The purpose of this study was to evaluate safety and efficacy of repeat radiosurgery for acromegaly. METHODS: Three hundred and ninety-eight patients with acromegaly treated with the Gamma Knife radiosurgery (Elekta AB, Stockholm) were identified from the International Gamma Knife Research Foundation database. Among these, 21 patients underwent repeated SRS with sufficient endocrine follow-up and 18 patients had sufficient imaging follow-up. Tumor control was defined as lack of adenoma progression on imaging. Endocrine remission was defined as a normal IGF-1 concentration while off medical therapy. RESULTS: Median time from initial SRS to repeat SRS was 5.0 years. The median imaging and endocrine follow-up duration after repeat SRS was 3.4 and 3.8 years, respectively. The median initial marginal dose was 17 Gy, and the median repeat marginal dose was 23 Gy. Of the 18 patients with adequate imaging follow up, 15 (83.3%) patients had tumor control and of 21 patients with endocrine follow-up, 9 (42.9%) patients had endocrine remission at last follow-up visit. Four patients (19.0%) developed new deficits after repeat radiosurgery. Of these, 3 patients had neurologic deficits and 1 patient had endocrine deficit. CONCLUSIONS: Repeat radiosurgery for persistent acromegaly offers a reasonable benefit to risk profile for this challenging patient cohort. Further studies are needed to identify patients best suited for this type of approach.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Alonso CE, Bunevicius A, Trifiletti DM, et al. Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study. J Neurooncol. 2019. PMID: 31541405. doi:10.1007/s11060-019-03296-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。